Overview

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a efficacy and safety study evaluating new treatment for subjects with mild to moderate Alzheimer's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Donepezil